三月 2026
lunsumio.com
显示 Similarweb 估计数据。
关联 GA4,公开验证您的网站指标
与您的成功同步
绑定 Google Analytics,验证您网站的流量及用户参与度指标
跳出率
91.43%
每次访问页数
1.16
平均访问时长
00:00:09
- 公司
- - -
- 行业
- - -
lunsumio.com的 10 大竞争对手
在 三月 2026 与 lunsumio.com 相似的前 10 名网站,按关键字流量、受众定位和市场重叠方面与 lunsumio.com 的关联性排名
Expands Natera’s lead in solid tumor MRD, acquiring ultrasensitive phased variant technology with LOD95 of 0.3 parts per million (ppm) and detection below 0 ...
- 公司
- - -
- 行业
- - -
跳出率
43.61%
每次访问页数
1.72
平均访问时长
00:00:23
Breyanzi® (lisocabtagene maraleucel) CAR T cell therapy treatment is used to treat adult patients with relapsed/refractory large B-cell lymphoma (LBCL). Please see full Prescribing Information, including Boxed WARNINGS and Medication Guide.
- 公司
- - -
- 行业
- - -
跳出率
77.1%
每次访问页数
1.43
平均访问时长
00:01:02
Learn about how YESCARTA® (axicabtagene ciloleucel) works. See full Prescribing Information, including BOXED WARNING.
- 公司
- - -
- 行业
- - -
跳出率
40.77%
每次访问页数
1.63
平均访问时长
00:01:09
Recommended dosing for TAZVERIK® (tazemetostat), an oral, twice-daily tablet for patients with advanced epithelioid sarcoma. Avoid coadministration of strong or moderate CYP3A inhibitors with TAZVERIK. If coadministration of strong or moderate CYP3A inhibitors cannot be avoided, reduce TAZVERIK dose. Avoid coadministration of moderate or strong CYP3A inducers with TAZVERIK, which may decrease the efficacy of TAZVERIK. Coadministration of TAZVERIK with CYP3A substrates, including hormonal contraceptives, can result in decreased concentrations and reduced efficacy of CYP3A substrates. See Important Safety Information and full Prescribing Information, including Medication Guide.
- 公司
- - -
- 行业
- - -
跳出率
41.62%
每次访问页数
1.49
平均访问时长
00:00:18
Find a list of questions to start a conversation with your doctor about POLIVY® (polatuzumab vedotin-piiq) plus R-CHP and DLBCL. See full safety information.
- 公司
- - -
- 行业
- - -
跳出率
91.36%
每次访问页数
1.25
平均访问时长
00:00:02
相似度评分
92%Learn about lupus nephritis, its causes, symptoms, and how GAZYVA® (obinutuzumab) may help. Explore resources for patients and caregivers. See Important Safety Information including Serious Side Effects for more information.
- 公司
- - -
- 行业
- - -
跳出率
78.31%
每次访问页数
1.28
平均访问时长
00:00:09
相似度评分
89%Find information about Herceptin® (trastuzumab), a treatment for HER2+ early and metastatic breast cancer and stomach cancer/GEJ. See full safety & Boxed Warnings for more information.
- 公司
- - -
- 行业
- - -
跳出率
43.69%
每次访问页数
1.54
平均访问时长
00:00:18
Learn about the financial assistance options for people taking Itovebi® (inavolisib), including for those who don't have insurance. See full safety for more information.
- 公司
- - -
- 行业
- - -
跳出率
92.53%
每次访问页数
1.13
平均访问时长
00:00:07
相似度评分
86%JELMYTO is the first and only FDA-approved treatment of low-grade upper tract urothelial cancer (LG-UTUC) in adult patients
- 公司
- - -
- 行业
- - -
跳出率
38.25%
每次访问页数
1.98
平均访问时长
00:00:11
相似度评分
85%learn about kisqali, a cdk4/6 inhibitor used to treat hr+/her2- metastatic breast cancer and early breast cancer. see full prescribing & safety info
- 公司
- - -
- 行业
- - -
跳出率
84.03%
每次访问页数
1.12
平均访问时长
00:00:06
lunsumio.com在 三月 2026 的前五名竞争对手是:foresight-dx.com、breyanzi.com、yescartahcp.com、tazverik.com等。
根据 Similarweb 的月访问量数据,lunsumio.com 在 三月 2026 的头号竞争对手是 foresight-dx.com。与 lunsumio.com 相似度排名第二的网站是 breyanzi.com,排名第三的是 yescartahcp.com。
在 三月 2026,tazverik.com 被评为与 lunsumio.com 相似度第四高的网站,polivy.com 位居第五。
进入前十名榜单的其他五家竞争对手分别是 gazyva.com、herceptin.com、itovebi.com、jelmyto.com 和 kisqali-hcp.com。